Form D · Pharmaceuticals
Incyclix Bio, LLC
Durham, NC · CIK 0001916275
Offering snapshot reported Aug 22, 2025 · SEC filing
- Reported sold
- $11.2M Offering amount: $20M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Aug 6, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 22, 2025 | Initial | $11,249,977 | No comparison | 4 | SEC filing |
| Jul 6, 2023 | Amendment | $14,952,930 | $2,952,990vs Mar 31, 2022 | 5 | SEC filing |
| Mar 31, 2022 | Initial | $11,999,940 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-555568
Source: Form D, filed Aug 22, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fredric N. Eshelman | Director, Executive |
| Patrick Roberts | Director, Executive |
| Norman Sharpless | Director |
| Sid Subramony | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
600 Park Offices Drive Suite 355
Durham, NC, 27713
Phone: (919) 328-0003
Durham, NC, 27713
Phone: (919) 328-0003